[Etanercept on steroid-refractary acute graft-versus-host disease].

Autor:	González Munguía S; Servicio de Farmacia Hospitalaria. Hospital Universitario de Gran Canaria Doctor Negrín. España.. silviaglezmunguia@hotmail.com., Pérez León M; Servicio de Farmacia Hospitalaria. Hospital Universitario de Gran Canaria Doctor Negrín. España.. silviaglezmunguia@hotmail.com., Piñero González M; Servicio de Farmacia Hospitalaria. Hospital Universitario de Gran Canaria Doctor Negrín. España.. silviaglezmunguia@hotmail.com., Díaz Pestano MM; Servicio de Farmacia Hospitalaria. Hospital Universitario de Gran Canaria Doctor Negrín. España.. silviaglezmunguia@hotmail.com., Molero Gómez R; Servicio de Farmacia Hospitalaria. Hospital Universitario de Gran Canaria Doctor Negrín. España.. silviaglezmunguia@hotmail.com., Luzardo Henríquez HD; Servicio de Hematología y Hemoterapia. Hospital Universitario de Gran Canaria Doctor Negrín. España.. silviaglezmunguia@hotmail.com.
Jazyk:	Spanish; Castilian
Zdroj:	Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria [Farm Hosp] 2015 May 01; Vol. 39 (3), pp. 147-51. Date of Electronic Publication: 2015 May 01.
DOI:	10.7399/fh.2015.39.3.8000
Abstrakt:	Unlabelled: Objetive: To describe etanercept use and effectiveness on steroid- refractary acute graft-versus-host disease after hematopoietic cell transplantation. Method: Patients treated with etanercept as off label use for steroid-refractary acute graft-versus-host disease were selected and each patient's medical history was reviewed to assess the clinical response. Results: The study included five patients: four presented with digestive manifestations and one presented pulmonary and liver manifestations. 80% of patients showed a clinical response: 60% a partial response and 20% a total response. In four cases etanercept 25mg was administered twice a week with variable duration of treatment, achieving no response in 1 case (3 weeks), partial response in two 2 cases (4 weeks and 8 weeks) and a complete response in 1 case (8 week period). Only one case was treated with etanercept 50mg administered twice a week for 5 weeks with a partial treatment response. Conclusions: The clinical response rate is consistent with the previously published data. This updates the scarce bibliographic information about etanecept use in steroid-refractary acute graft-versus-host disease. Due to clinical design limitations and the small patient population, future clinical studies should be conducted to assess the efficacy and security of etanercept in these patients. (Copyright AULA MEDICA EDICIONES 2014. Published by AULA MEDICA. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu